Cardiology Highlight Reel 2015 – Lipids

Details & Video

Lipids

Learn how to select the right patient for a PCSK9 inhibitor!

Join Dr. Kausik Ray in conversation discussing where LDL-C targets may be going, the association between statins and new onset diabetes, and the introduction of new lipid-lowering drugs.

Lipid management and the new PCSK9 inhibitors
Video Time: 25 min (Chapter selection enabled)
Program Interactivity: 5 min
CME Credits:This program is eligible for MOC RCPSC, Section 2 credits or you are eligible to claim up to 5 Mainpro+ certified credits by completing the CFPC’s Linking Learning to practice exercise.
Target Audience: Family Physicians, Cardiologists, Internists, Endocrinologists, Nephrologists

 

Program Preview

Click image above to play the program preview.



To watch the full program,
please login or register

 

Program Overview

The Cardiology Highlight Reel 2015 series engages world-renowned experts in conversation about the most important advances in cardiovascular medicine in 2015. Presented in short interviews, this program is a must-see for all clinicians managing patients with, or at risk for, cardiovascular disease.

In this segment, Dr. Kausik Ray discusses where LDL-C targets may be going, the association between statins and new onset diabetes, and the introduction of new lipid-lowering drugs.

Participate in this eCME and stay informed!

Cardiology Highlight Reel program flyer

CME Credits

This program is eligible for MOC RCPSC, Section 2 credits or you are eligible to claim up to 5 Mainpro+ certified credits by completing the CFPC’s Linking Learning to practice exercise.

You will receive your Certificate of Completion following participation in the interactive program elements located under the “Certificate” tab in the program player window. A link to the Linking Learning to Practice exercise on the CFPC website will be included in your certificate.

Faculty


Potential for conflicts of interest:

Some speakers in this program have received payment/funding from the organizations supporting this program.
Speaker disclosures will be declared within the presentations.

Dr.-Milan-Gupta Co-Chair
Milan Gupta, MD, FRCPC, FACC
Associate Clinical Professor, Dep’t of Medicine
McMaster University
Assistant Professor, Department of Medicine,
University of Toronto, Medical Director
Canadian Cardiovascular Research Network
Brampton, ON
Dr.Narendra Singh Co-Chair
Narendra Singh, MD, FRCPC, FACC, FAHA
Director, Clinical Research
Atlanta Heart Specialists
Clinical Assistant Professor
Georgia Regents University
Atlanta, GA
Dr. Kausik Ray Guest Faculty
Kausik Ray, MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FESC, FACC, FAHA
School of Public Health
Imperial College London
London, UK

Agenda

 

Introduction 1.5 min
Statins and Diabetes

  • Association or causality?
  • Mechanisms
3.5 min
IMPROVE-IT

  • Clinical Implications
4 min
CETP Inhibitors

  • Evacetrapib
  • Anacetrapib
4 min
PCSK9-Inhibitors

  • Mechanism of action
  • LDL-C efficacy
  • Role in clinical practice
4 min
Who Should Be Eligible for PCSK9 Inhibitors?

  • Statin Side Effects/ Intolerance
  • High Absolute CVD Risk
  • Familial Hypercholesterolemia
3 min
Discussion 5 min

Sponsorship

CCRN sm

This program has been developed by the Canadian Cardiovascular Research Network, a not-for-profit academic research and CHE organization, and is supported through educational grants received from:

 

  • Amgen Canada
  • AstraZeneca Canada
  • Boehringer Ingelheim Canada
  • Sanofi Canada